论文部分内容阅读
目的观察比较围绝经期功能失调性子宫出血患者给予米非司酮和曼月乐缓释系统治疗的临床效果。方法选取医院收治的86例围绝经期功能失调性子宫出血患者作为研究对象,随机分为对照组和观察组,每组43例。对照组给予米非司酮治疗,观察组给予曼月乐缓释系统治疗。观察2组患者临床疗效及不良反应发生情况。结果观察组各时间段子宫内膜厚度、月经量均明显低于对照组(P<0.01),血红蛋白含量明显高于对照组(P<0.01)。观察组不良反应发生率为9.3%,低于对照组的25.6%(P<0.05)。结论在围绝经期功能失调性子宫出血患者的临床治疗过程中给予曼月乐缓释系统治疗可获得显著效果,且安全性高,值得临床推广应用。
Objective To compare the clinical efficacy of mifepristone and Mirena sustained-release system in patients with dysfunctional uterine bleeding during peri-menopausal period. Methods Totally 86 patients with dysfunctional uterine bleeding in perimenopausal period were enrolled in the study. They were randomly divided into control group and observation group, with 43 cases in each group. The control group was given mifepristone treatment, and the observation group was treated with Mirena sustained-release system. The clinical efficacy and adverse reactions of the two groups were observed. Results The endometrial thickness and menstrual flow in the observation group were significantly lower than those in the control group (P <0.01). The hemoglobin content in the observation group was significantly higher than that in the control group (P <0.01). The incidence of adverse reactions in the observation group was 9.3%, which was lower than that in the control group (25.6%, P <0.05). Conclusion In the clinical treatment of patients with dysfunctional uterine bleeding during peri-menopausal period, Mirena sustained-release system is effective and safe. It is worthy of clinical application.